Dr. De Alba will discuss preclinical studies that show the potential of the Company’s lead clinical asset, ‘1104, for treating atopic dermatitis (AD). In a chronic allergen-driven murine model of AD, ...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, July 24, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced new data from preclinical studies and previously completed ...

In multiple preclinical models evaluated in single-dose toxicity studies, there were no ‘1104-related local tolerability adverse effects after treatment with the ‘1104 SQ formulation at dose levels ...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced its decision to accelerate the advancement of a sublingual, ...

NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term ...

NEW ORLEANS and CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...

- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics ...

-- Data continues to differentiate '1104 as a potential allergic disease treatment that acts upstream in the immune cascade -- '1104 reduces key indices of skin inflammation and inflammatory mediators ...

Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 ...

Data continues to differentiate '1104 as a potential allergic disease treatment that acts upstream in the immune cascade '1104 reduces key indices of skin inflammation and inflammatory mediators in a ...